ROCHE DIAGNOSTICS partners with ISL to expand TROP T Rapid assay in India (13/Jan/2012) Ind-Swift Group is Chandigarh based pharmaceutical Group, established in 1986 with a mission of winning global customers through innovative pharmaceutical products. Three visionaries Jains, Mehtas and Munjals, dedicated themselves to work for humanity's quest for longer, happier and healthier lives. With a turnover of Rs 1800 Crores IND-SWIFT group has been ranked 35th among top Indian Pharmaceutical Companies is regarded as the most promising pharmaceutical group in India by both IMS and ORG-marg. IND-SWIFT is ISO 9001-2008, WHO GMP certified and is listed on Bombay Stock Exchange and National Stock Exchange. IND-SWIFT is committed to offer quality and innovative products to all its clients globally. We ensure value for money by developing innovative therapies and process to produce safe, effective and consistent quality products. IND-SWIFT is a research driven forward looking pharmaceutical group having world class expertise in finished goods dosage. Today IND-SWIFT is proud to be the second largest group in North India. IND-SWIFT's product range includes Active Pharmaceutical Ingredients (API's), Finished Drug Formulation (FDF's) & Herbal products.
Ind-Swift has some of the strongest brands in India and demonstrated to build brands and leadership through markets characterized by intense competition. The Group's strategy of leveraging its competencies, build assiduously over the years through a growing domestic market, and addressing manufacturing opportunities in the developed global pharmaceutical markets sharply defines its strategies intent. The group has dedicated R&D department focused strong competencies for its wide range of products .It is equipped with the latest equipments and supported by scientists who continuously work hard to produce innovative products.
The Group is one of the largest manufacturers of macrolide worldwide, and enjoys leadership position in the Clarithromycin, Clarithromycin Granules, Azithromycin, and has around 23% of the global market share for Clarithromycin. Apart from pharmaceutical business IND-SWIFT has also progressively forayed in diversification into multifarious fields viz Infrastructure, Printing & Packaging and Stationary, Education, and Media Publication with its every unit as an independent profit earning centre. At IND-SWIFT we are committed to give our unflinching efforts, support and dedication for the service of mankind because we believe "Life is precious"
ROCHE DIAGNOSTICS partners with ISL to expand TROP T Rapid assay in India (13/Jan/2012)
Ind-Swift Group is Chandigarh based pharmaceutical Group, established in 1986 with a mission of winning global customers through innovative pharmaceutical products. Three visionaries Jains, Mehtas and Munjals, dedicated themselves to work for humanity's quest for longer, happier and healthier lives. With a turnover of Rs 1800 Crores IND-SWIFT group has been ranked 35th among top Indian Pharmaceutical Companies is regarded as the most promising pharmaceutical group in India by both IMS and ORG-marg. IND-SWIFT is ISO 9001-2008, WHO GMP certified and is listed on Bombay Stock Exchange and National Stock Exchange. IND-SWIFT is committed to offer quality and innovative products to all its clients globally. We ensure value for money by developing innovative therapies and process to produce safe, effective and consistent quality products. IND-SWIFT is a research driven forward looking pharmaceutical group having world class expertise in finished goods dosage. Today IND-SWIFT is proud to be the second largest group in North India. IND-SWIFT's product range includes Active Pharmaceutical Ingredients (API's), Finished Drug Formulation (FDF's) & Herbal products.
